This handout is for pleural infection / empyema. Your care team identified this based on: pneumonia with persistent/recrudescent fever or failure to improve on antibiotics + new/enlarging effusion (bts 2023 roberts pmid 37553157).
Other reasons your team may use this plan: pleural effusion / loculated collection complicating pneumonia on cxr / lung ultrasound / ct (bts 2023); frank pus on aspiration, pleural ph <7.20, or positive pleural gram stain/culture (bts 2023; heffner 1995 pmid 7767510); sepsis / septic shock with a pleural collection — pleural-space source (bts 2023; ssc 2026).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| ampicillin-sulbactam | 3 g IV q6h | IV | q6h (treat source pneumonia; reassess effusion 24-48 h) | Treat antecedent pneumonia + obligatory anaerobic cover should the effusion progress (BTS 2023; route to pulm.cap.core.v1) |
| ceftriaxone | CTX 2 g IV q24h + metronidazole 500 mg IV q8h | IV | CTX q24h + metronidazole q8h | Alternative community regimen; metronidazole supplies the obligatory anaerobic cover (BTS 2023) |
Plan: BTS 2023 + MIST2 + ACCP — parapneumonic staging, acquisition-route antibiotics, drainage ladder
Call 911 or go to the nearest emergency room right away if you have:
Complete prolonged antibiotic course (2-6 weeks; longer for organising empyema), follow-up imaging to radiographic resolution, nutritional rehabilitation, source-pneumonia / aspiration-risk workup, return-to-work counselling (~4 wk; Meggyesy 2024 PMID 39037060)
Guideline: BTS 2023 Guideline for Pleural Disease (Roberts, Thorax 2023) — pleural infection; with MIST2 (intrapleural tPA+DNase), MIST1 (streptokinase null), RAPID/PILOT (mortality risk), Heffner pH meta-analysis, ACCP parapneumonic guideline